PCSK9-targeting therapies were associated with lower all-cause mortality and fewer ischemic events across trial populations, and the predominant contribution of large cardiovascular outcome trials enrolling populations with known atherosclerosis and using PCSK9 antibodies limits the ability to infer a survival benefit.
E. Navarese, E. Ruscio, Hai-Xiang Zheng et al.· European Journal of Preventi...· 0 citations
In CKD patients not yet on kidney replacement therapy, systemic low-grade inflammation, measured through hs-CRP, is associated with occurrence of cardiovascular events independently of traditional risk factors, including a history of ASCVD.
J. Motiejūnaitė, Leila Benamara, Emilie Moutard et al.· European Journal of Preventi...· 0 citations
AIMS
To assess the demographic, clinical, behavioural, and treatment factors associated with health-related quality of life (HRQoL) in heart failure (HF), examine the association between HRQoL and mortality, and evaluate changes in HRQoL over 1-year.
METHODS
We analysed the ESC EORP Heart Failure III Registry, includ...
M. Walli-Attaei, L. Lund, R. Luengo-Fernandez et al.· European Journal of Heart Fa...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.